SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 11768.
  • 2
    Tangrea J, Helzlsouer K, Pietinen P, Taylor P, Hollis B, Virtamo J, Albanes D. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997; 8: 61525.
  • 3
    Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 84752.
  • 4
    Ross TK, Darwish HM, DeLuca HF. Molecular biology of vitamin D action. Vitam Horm 1994; 49: 281326.
  • 5
    Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994; 23: 11336.
  • 6
    Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002; 94: 186775.
  • 7
    Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case- control study in Mexico. Oncology 2002; 63: 1517.
  • 8
    Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000; 86: 406.
  • 9
    Saunders DE, Christensen C, Lawrence WD, Malviya VK, Malone JM, Williams JR, Deppe G. Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol 1992; 44: 1316.
  • 10
    Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, Malone JM, Deppe G. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993; 4: 2018.
  • 11
    Hansen CM, Binderup L, Hamberg KJ, Carlberg C. 2001. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 2001; 6: D82048.
  • 12
    Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 88894.
  • 13
    Jones G, Ramshaw H, Zhang A, Cook R, Byford V, White J, Petkovich M. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 1999; 140: 330310.
  • 14
    Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E, Peterlik M. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001; 66: 28792.
  • 15
    Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001; 61: 28526.
  • 16
    Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001; 357: 16734.
  • 17
    Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998; 7: 3915.
  • 18
    Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 2001; 98: 7498503.
  • 19
    Sakaki T, Sawada N, Nonaka Y, Ohyama Y, Inouye K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem 1999; 262: 438.
  • 20
    Seo EG, Einhorn TA, Norman AW. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 1997; 138: 386472.
  • 21
    Rashid SF, Mountford JC, Gombart AF, Campbell MJ. 1alpha,25-dihydroxyvitamin D(3) displays divergent growth effects in both normal and malignant cells. Steroids 2001; 66: 43340.
  • 22
    Armbrecht HJ, Boltz MA. Expression of 25-hydroxyvitamin D 24-hydroxylase cytochrome P450 in kidney and intestine. Effect of 1,25-dihydroxyvitamin D and age. FEBS Lett 1991; 292: 1720.
  • 23
    Rubin LP, Yeung B, Vouros P, Vilner LM, Reddy GS. Evidence for human placental synthesis of 24,25-dihydroxyvitamin D3 and 23,25-dihydroxyvitamin D3. Pediatr Res 1993; 34: 98104.
  • 24
    Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 1446.
  • 25
    Christopherson WA, Porter JC, MacDonald PC, Casey ML. Responsiveness of human carcinoma cells of gynecologic origin to 1,25-dihydroxycholecalciferol. Am J Obstet Gynecol 1986; 155: 12936.
  • 26
    Roy S, Martel J, Tenenhouse HS. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase. J Bone Miner Res 1995; 10: 19519.
  • 27
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 195260.
  • 28
    Harant H, Spinner D, Reddy GS, Lindley IJ. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem 2000; 78: 11220.
  • 29
    Munker R, Norman A, Koeffler HP. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986; 78: 42430.
  • 30
    Love-Schimenti CD, Gibson DF, Ratnam AV, Bikle DD. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer Res 1996; 56: 278994.
  • 31
    Klaus G, Weber L, Rodriguez J, Fernandez P, Klein T, Grulich-Henn J, Hugel U, Ritz E, Mehls P. Interaction of IGF-I and 1 alpha, 25(OH)2D3 on receptor expression and growth stimulation in rat growth plate chondrocytes. Kidney Int 1998; 53: 115261.
  • 32
    Gniadecki R. Stimulation versus inhibition of keratinocyte growth by 1,25- Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996; 106: 5106.
  • 33
    Rots NY, Iavarone A, Bromleigh V, Freedman LP. Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999; 93: 27219.
  • 34
    Grenman S, Engblom P, Rantanen V, Klemi P, Isola J. Cytogenetic characterization of five new ovarian carcinoma cell lines. Acta Obstet Gynecol Scand 1997; 76: 83.
  • 35
    Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989; 182: 169.
  • 36
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: 20027.
  • 37
    Turnbull H, Trafford DJ, Makin HL. A rapid and simple method for the measurement of plasma 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 using Sep-Pak C18 cartridges and a single high-performance liquid chromatographic step. Clin Chim Acta 1982; 120: 6576.
  • 38
    Parviainen MT, Savolainen KE, Korhonen PH, Alhava EM, Visakorpi JK. An improved method for routine determination of vitamin D and its hydroxylated metabolites in serum from children and adults. Clin Chim Acta 1981; 114: 23347.
  • 39
    Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 1984; 58: 918.
  • 40
    Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 1996; 316(Pt 2) 36171.
  • 41
    Gross C, Peehl DM, Feldman D. Vitamin D and prostate cancer. In: FeldmanD, GlorieuxFH, PikeJW. Vitamin D. San Diego: Academic Press, 1997. 112539.
  • 42
    VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998; 139: 210210.
  • 43
    Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, Black MJ, Alaoui-Jamali MA, White JH. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J Natl Cancer Inst 2001; 93: 74553.
  • 44
    Wang X, Chen X, Akhter J, Morris DL. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Br J Urol 1997; 80: 2602.
  • 45
    James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 1994; 141: 55563.
  • 46
    Hansen CM, Hamberg KJ, Binderup E, Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 2000; 6: 80328.
  • 47
    Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997; 138: 14917.
  • 48
    Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998; 78: 613.
  • 49
    Chen KS, DeLuca HF. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995; 1263: 19.
  • 50
    Kerry DM, Dwivedi PP, Hahn CN, Morris HA, Omdahl JL, May BK. Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter. J Biol Chem 1996; 271: 2971521.
  • 51
    Ohyama Y, Ozono K, Uchida M, Yoshimura M, Shinki T, Suda T, Yamamoto O. Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 1996; 271: 303815.
  • 52
    Campbell MJ, Drayson MT, Durham J, Wallington L, Siu-Caldera ML, Reddy GS, Brown G. Metabolism of 1alpha,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation. Mol Cell Endocrinol 1999; 149: 16983.
  • 53
    Schuster I, Egger H, Bikle D, Herzig G, Reddy GS, Stuetz A, Stuetz P, Vorisek G. Selective inhibition of vitamin D hydroxylases in human keratinocytes. Steroids 2001; 66: 40922.
  • 54
    Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 18339.
  • 55
    Hahn CN, Baker E, Laslo P, May BK, Omdahl JL, Sutherland GR. Localization of the human vitamin D 24-hydroxylase gene (CYP24) to chromosome 20q13.2-q13.3. Cytogenet Cell Genet 1993; 62: 1923.
  • 56
    Rustin GJ, Quinnell TG, Johnson J, Clarke H, Nelstrop AE, Bollag W. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 1996; 74: 147981.
  • 57
    Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH. Regulation of gene expression by 1alpha,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 2001; 15: 112739.
  • 58
    Shankar VN, Dilworth FJ, Makin HL, Schroeder NJ, Trafford DJ, Kissmeyer AM, Calverley MJ, Binderup E, Jones G. Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem Pharmacol 1997; 53: 78393.
  • 59
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000; 9: 26570.
  • 60
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000; 6: 9018.
  • 61
    Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, Moss SF, Fan K, Yang K, Lipkin M. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11: 1139.
  • 62
    Collins ED, Norman AW. Vitamin D. In: RuckerRB, SuttieJW, McCormickDB, MachlinLJ. Handbook of vitamins. New York: Marcel Dekker, 2001. 51113.
  • 63
    Omdahl J, May B. The 25-hydroxyvitamin D 24-hydroxylase. In: FeldmanD, GlorieuxFH, PikeJW. Vitamin D. San Diego: Academic Press, 1997. 6985.